This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Peregrine Pharmaceuticals, Inc.
Drug Names(s): Tarvacin, 3G4
Description: Bavituximab is a chimeric anti-phosphatidylserine monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress.
Bavituximab binds to various aminophospholipids and is dependent on interaction with plasma protein beta2-glycoprotein 1 to mediate binding. These target aminophospholipids, usually residing only on the inner leaflet of the plasma membrane of cells are purportedly only exposed in virally infected, damaged or malignant cells.
Bavituximab is an investigational immunotherapy designed to assist the body's immune system by targeting and modulating the activity of phosphatidylserine (PS), a highly immune-suppressive signaling molecule expressed broadly on the surface of cells in the tumor microenvironment. Peregrine's PS signaling pathway inhibitor candidates, including bavituximab, reverse the immunosuppressive environment that many tumors establish in order to proliferate, while also activating immune cells that target and fight cancer. The preclinical equivalent of bavituximab, ch1N11, is used in animal model studies as a guide for clinical development.
Additional information available to subscribers only: